全文获取类型
收费全文 | 359篇 |
免费 | 28篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 16篇 |
妇产科学 | 4篇 |
基础医学 | 83篇 |
口腔科学 | 13篇 |
临床医学 | 25篇 |
内科学 | 98篇 |
皮肤病学 | 30篇 |
神经病学 | 36篇 |
特种医学 | 1篇 |
外科学 | 35篇 |
预防医学 | 13篇 |
眼科学 | 1篇 |
药学 | 17篇 |
中国医学 | 6篇 |
肿瘤学 | 5篇 |
出版年
2022年 | 4篇 |
2021年 | 6篇 |
2019年 | 9篇 |
2018年 | 7篇 |
2017年 | 3篇 |
2016年 | 5篇 |
2015年 | 8篇 |
2014年 | 8篇 |
2013年 | 10篇 |
2012年 | 12篇 |
2011年 | 23篇 |
2010年 | 16篇 |
2009年 | 10篇 |
2008年 | 21篇 |
2007年 | 17篇 |
2006年 | 17篇 |
2005年 | 12篇 |
2004年 | 13篇 |
2003年 | 23篇 |
2002年 | 19篇 |
2001年 | 14篇 |
2000年 | 17篇 |
1999年 | 14篇 |
1998年 | 6篇 |
1997年 | 6篇 |
1996年 | 2篇 |
1995年 | 4篇 |
1993年 | 1篇 |
1992年 | 12篇 |
1991年 | 4篇 |
1990年 | 3篇 |
1989年 | 4篇 |
1988年 | 5篇 |
1987年 | 5篇 |
1986年 | 7篇 |
1985年 | 4篇 |
1984年 | 7篇 |
1983年 | 3篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 8篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1976年 | 1篇 |
1974年 | 2篇 |
1969年 | 1篇 |
1968年 | 1篇 |
1967年 | 1篇 |
1966年 | 2篇 |
排序方式: 共有388条查询结果,搜索用时 15 毫秒
41.
F Nú?ez O Domínguez E Coto C Suárez-Nieto P Pérez C López-Larrea 《Surgical oncology》1992,1(6):405-411
The presence of proto-oncogene mutations at codons 12, 13 and 61 of the Ha-, Ki-, and N-ras in primary head and neck squamous cell carcinoma are analysed in this study. Oncogene ras-specific sequences were amplified by the polymerase chain reaction and probed with mutation specific oligonucleotide probes. Mutations were detected in 8 of 22 samples (36.3%). No mutations were detected on patients' peripheral blood DNA. We found that histologically and clinically, squamous cell carcinomas with or without a ras mutation do not differ significantly from each other. 相似文献
42.
Pilar A Sáiz Maria P García-Portilla Begoña Paredes Celso Arango Blanca Morales Victoria Alvarez Eliecer Coto E Teresa Bascarán Manuel Bousoño Julio Bobes 《Behavioral and brain functions : BBF》2007,3(1):32-3
Objective
The aim of this study is to investigate the association between two polymorphisms of endothelial nitric oxide synthase (NOS3) and suicide attempts. 相似文献43.
Fernández Angela Gómez Juan Alonso Belén Iglesias Sara Coto Eliecer 《Journal of molecular neuroscience : MN》2015,56(3):613-616
Journal of Molecular Neuroscience - Our purpose was to develop a next-generation sequencing procedure to search for NOTCH3 and HTRA1 mutations in patients with cerebral autosomal dominant... 相似文献
44.
Custom‐made facemask as a coadjuvant in the postoperative treatment of sport‐related facial trauma: Case report 下载免费PDF全文
Leonardo Santos Antunes Ariane Ferraz Corrêa Torres Gustavo Ferreira Roberto Prado Neide Pena Coto Lívia Azeredo Alves Antunes 《Dental traumatology》2018,34(5):378-381
Maxillofacial injuries are a regular consequence of sport activities that can force athletes to take a long time off from training and competitions. One way to decrease the time that the athlete needs to get back to his or her training exercises after surgery is to use a custom facemask as a coadjuvant in the postoperative recovery phase. This case report describes the case of a 16‐year‐old male athlete who suffered facial trauma (orbitozygomatic fractures) during a soccer game. After surgery, a facemask was used during the postoperative phase. He returned to his regular physical activities only 3 weeks after surgery. This simple and very efficient procedure is a good option for athletes who suffer facial injuries. 相似文献
45.
46.
Vincenzo Coto Manlio Cocozza Ugo Oliviero Antonio Lucariello Tommaso Picano Biagio Castaldo Vincenzo Iovino Luigi Cacciatore 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》1990,4(1):77-80
Summary It is now generally accepted that antihypertensive therapy can induce regression of left ventricular hypertrophy (LVH) in hypertensive subjects. However, the influence of LVH reversal on both the systolic and diastolic functions, and particularly the ability of the heart to meet sudden overloads caused by exercise and/or recurrence of hypertension, remain unanswered questions. The long-term effects of ketanserin, a selective serotonin S2-receptor antagonist with additional alpha1-adrenergic blocking properties, on LVH and systolic function were studied in 13 untreated subjects (age range 35–55 years) with mild-to-moderate essential hypertension, echocardiographic evidence of LVH, and normal ejection fraction. Blood pressure values and echocardiographic measurements of dimensions, wall thicknesses, and indices of LV mass were determined before and after 3, 6, and 12 months treatment; ejection fractions at rest and during exercise were evaluated by equilibrium multigated radionucleide angiocardiography at baseline and after 12 months of therapy. Mean arterial pressure was significantly reduced from the first month of treatment (p<0.001) and remained well controlled up to the end of the trial. Both posterior and septum wall thicknesses decreased after 3 months of therapy and remained stable throughout the whole study period. LV mass index decreased from a mean ± SD of 187.7±47.6 g/m2 to a mean of 157.81±31.63 g/m2 (p<0.01) at the third month, reaching greater decreases after 6 months (156.05±31.00 g/m2) and after 12 months (153.21±28.80 g/m2) of treatment. A significant correlation was found between LV mass and posterior wall thickness at the different observation times in the study. Finally, the regression of LVH at the end of therapy was not associated with impairment of systolic function, as assessed by measurements of ejection fraction at rest and during exercise. 相似文献
47.
48.
49.
50.
Coto V Oliviero U Sorrentino P Cocozza M Ciarimboli M Lingetti M 《Archives of gerontology and geriatrics》1992,15(3):215-223
Idebenone (45 mg twice daily) was administered to 7 patients with moderate renal impairment (creatinine clearance 21-40 ml/min) for 10 days. Standard pharmacokinetic parameters were computed on day 1 (single administration) and on day 10. On day 1 the mean of the maximum plasma concentration values (C(max)) was 364 ng/ml (standard deviation (S.D.) 100); time to C(max) (t(max)) was in the range of 1-2 h for 6 patients and 12 h for the remaining patient: the mean was 3 h (S.D. 3.99); the mean area under the plasma concentration vs. time curve (AUC) was 3005 ng h/ml (S.D. 1152). On day 10 the mean C(max) was 531 ng/ml (S.D. 355.3), the mean t(max) was 0.07 h (S.D. 0.19), the mean AUC was 3167 ng/ml (S.D. 2944) and the mean elimination half-life (t(1/2)) was 4.9 h (S.D. 1.1). Idebenone metabolites (QS-4, QS-6 and QS-10) showed a kinetic profile similar to the parent compound, with pharmacokinetic parameters comparable to idebenone for QS-4 and lower than idebenone for QS-6 and QS-10. Idebenone was metabolized and easily excreted and no accumulation was observed for the compound and its metabolites. No significant modification of the biohumoral indexes and vital signs and no adverse reactions were observed. 相似文献